Promis Neurosciences Inc 's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics

What is ROE for Promis Neurosciences Inc in the second quarter 2026?
Promis Neurosciences Inc recorded a cumulative net loss of $-42 million during 12 months ending in the second quarter 2026, resulting in a negative return on equity (ROE) of -143.09%.

Within the Major Pharmaceutical Preparations industry 284 other companies had a higher return on equity. While return on equity, the total ranking has deteriorated compared to the first quarter 2026 from 3440 to 3765.

What is ROE?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Equity ROE▼

None ▼

Return on Equity ROE▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Equity	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Equity Change	-	541.04 %	-	26.32 %	-
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in Millions	-42	-41	-40	-29	-8
Return On Equity (TTM)	-143.09 %	-237.99 %	-933.58 %	-336.93 %	-102.61 %
PMN's Total Ranking	# 3765	# 3440	# 3473	# 3565	# 3038
Equity (TTM) in Millions	49	61	-1	9	0
Seq. Equity Change	-18.64 %	-	-	-	-
Seq. Net Income Change	-	-	-	-	-

Back to PMN Management Effectiveness >> PMN's 5 Years Annual ROE >> Compare PMN ROE to its Competitors

Return On Equity Company Ranking
Within:	No.
Industry	# 285
Sector	# 612
Overall	# 3765

Return On Equity Statistics
High	Average	Low
51.55 %	-463.94 %	-2311.75 %
(Dec 31 2024)		(Mar 31 2024)

News about Promis Neurosciences inc Return on Equity ROE

ProMIS Neurosciences CEO Neil Warma to Showcase Groundbreaking Neurodegenerative Therapies at H.C. Wainwr...

CAMBRIDGE, Massachusetts and TORONTO, Ontario, September 5, 2024 - ProMIS Neurosciences Inc. (Nasdaq: PMN), a biotech firm at the cutting edge of the fight against neurodegenerative diseases, has confirmed its participation at the prestigious H.C. Wainwright 26th Annual Global Investment Conference. The event, a significant gathering of top-tier investors and companies, will take place on September 9 and 10, 2024.Neil Warma, Chief Executive Officer of ProMIS Neurosciences, is set to represent the company at this influential conference. Mr. Warma will not only participate in the event s key discussions and presentations but will also conduct a series of one-on-one meetings with potential investors, collaborators, and other key stakeholders. These meetings are designed to provide an in-depth understanding of ProMIS Neurosciences’ groundbreaking work and its future directions.

PMN Annual Return On Equity	(Dec 31 2025) 2025	(Dec 31 2024) 2024	(Dec 31 2023) 2023	(Dec 31 2022) 2022
Total Equity in Millions	-1	16	4	-1	0
Y / Y Equity Change	-	339.3 %	-	-	-
Net Income in Millions	-40	3	-13	-18	0
Y / Y Net Income Change	-	-	-	-	-
Return On Equity	-	16.85 %	-352.02 %	-	-

Back to PMN Management Effectiveness >> PMN's 5 Years Annual ROE >> Compare PMN ROE to its Competitors

More Return On Equity Ratios
Major Pharmaceutical Preparations Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
PMN's' Return on Equity at Yahoo Finance
PMN's Roe Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for PMN's Competitors
Subscribers only: Roe for Promis Neurosciences Inc 's Suppliers
Subscribers only: Return On Equity for PMN's Customers

Companies with similar Return On Equity at Jun 30 2026, within Healthcare Sector

ROE

Date modified: 2026-09-03T06:21:26+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.